News & Events about Biomea Fusion Inc.
BMF-500, a novel 3rd generation covalent inhibitor of fms-like tyrosine kinase 3 (FLT3), is the second investigational compound, discovered and developed by Biomeas FUSION System, to advance to the clinic.Phase I study (COVALENT-103) of BMF-500 will examine its safety and efficacy in patients with ...
New clinical data from COVALENT-111 will be featured during the Late-Breaking Poster Presentations at the Scientific SessionsBiomea to hold an investor and KOL event during the Scientific Sessions REDWOOD CITY, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea) (Nasdaq: BMEA), a...
REDWOOD CITY, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea or the Company) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined ...
Globe Newswire
2 months ago
REDWOOD CITY, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and ...
Globe Newswire
2 months ago
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and ...